国际医药卫生导报2018，Vol.24Issue(15)：2354-2357,4.DOI:10.3760/cma.j.issn.1007-1245.2018.15.039
利妥昔单抗治疗甲状腺相关眼病的系统评价
The relationship between thyroid associated ophthalmopathy and rituximab: a systematic review
岳欣欣 1傅全威 2付洋2
作者信息
- 1. 110163沈阳,辽宁何氏医学院内科学教研室
- 2. 110840 沈阳军区总医院医疗科
- 折叠
摘要
Abstract
Objective To systematically evaluate the relationship between thyroid associated ophthalmopathy (TAO) and rituximab (RTX).Methods We electronically searched the CNKI,Cqvip,WanFang Data,PubMed,and EMbase databases to collected randomized controlled trials (RCTs) or cohort study about the association between thyroid associated ophthalmopathy and rituximab from January 2006 to March 2016.Two reviewers independently screened literature according to the inclusion and exclusion criteria.Results A total of 6 studies were included in the systematic review.All studies showed that rituximab could be used to treat thyroid associated ophthalmopathy.Conclusion Due to the small sample size in this Meta analysis,more RCTs of high quality and large scale are needed to be performed in the future.关键词
利妥昔单抗/甲状腺相关眼病/治疗/系统评价Key words
Rituximab/Thyroid associated ophthalmopathy/Treatment/Systematic review引用本文复制引用
岳欣欣,傅全威,付洋..利妥昔单抗治疗甲状腺相关眼病的系统评价[J].国际医药卫生导报,2018,24(15):2354-2357,4.
